Eli Lilly Expands Early Access to Experimental Obesity Drug Ahead of Approval
Indianapolis, Tuesday, 4 August 2026.
Eli Lilly is expanding its compassionate use program to offer select, high-risk patients early access to retatrutide—an unapproved drug that has demonstrated unprecedented weight loss of up to 28% in clinical trials.
Eligibility Criteria and Program Expansion
Eli Lilly (NYSE: LLY) confirmed on Monday, 3 August 2026, that it is expanding its compassionate use program to allow more patients to apply for early access to retatrutide [1][5]. Eligible patients must be aged 18 or older and demonstrate refractory obesity despite tolerating the highest approved dose of obesity therapy [5]. Additionally, candidates must have at least two serious or life-threatening obesity-related complications for which they are receiving care [5]. This policy shift follows inquiries from healthcare providers after the company initially granted special access to a single 79-year-old patient [1][4]. A company spokesperson stated that for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, it is medically appropriate to make authentic retatrutide available before FDA approval [5].
Clinical Performance and Mechanism of Action
Retatrutide functions as a triple hormone agonist, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors [2]. In phase 3 clinical trials, participants on the highest dose achieved an average weight loss of approximately 28% of their starting body weight over 80 weeks [2]. In a separate trial focusing on adults with severe obesity and established heart disease, the average weight loss was 22.6% over the same duration [5]. The variance in weight loss efficacy between the general phase 3 cohort and the heart disease cohort is 5.4 percentage points [2][5]. Unlike existing treatments such as Wegovy and Zepbound, retatrutide’s unique glucagon receptor activity is designed to accelerate metabolism while preventing hyperglycemia [2].
Regulatory Timeline and Market Implications
The manufacturer intends to submit an application for FDA approval in the first quarter of 2027, with potential regulatory approval anticipated later that same year [2][5]. This timeline assumes a standard review duration of 6 to 10 months following submission [2]. Concurrently, investigations into compounded GLP-1 weight loss drugs highlight safety concerns, as compounded drugs are not FDA-approved and their quality is not verified before marketing [6]. The expanded access program aims to bridge the gap for high-risk patients while maintaining regulatory compliance ahead of the anticipated 2027 launch [3][5].